Shares of Denali Therapeutics (DNLI) dropped significantly in after-hours trading following the news that its Phase 2 study of oditrasertib for multiple sclerosis was discontinued due to failure to meet primary and secondary endpoints. The company is expected to provide further details on the study’s termination during its upcoming earnings call.
Valneva and Pfizer announced positive immunogenicity and safety data from their Phase 2 study of a second booster dose for their Lyme disease vaccine candidate, VLA15. The data shows a robust immune response and a favorable safety profile, with the second booster providing similar benefits to the first. The companies are currently conducting two Phase 3 trials with the goal of submitting marketing applications to the FDA and EMA in 2026.
